ActiTrexx

The goal of ActiTrexx is to prevent GvHD at an early stage with the cellular therapy ATreg and to provide a curative therapy with few side effects for patients with blood stem cell transplantation for the first time.

ActiTrexx operates in immunology based in Germany, founded in 2021.

The company sits in the immunology segment, where it competes on its core product or service.

Its base of operations is Germany.

Its current recorded stage is VC-backed startup.

Website: actitrexx.de